Vici was founded by Dr. Anish Dhanarajan, PhD and Francesca Minale, MEng in 2016 with the goal of becoming a world class pharmaceutical product development company. Vici works hard at identifying unmet pharmaceutical needs that can be solved by drug development through the 505(b)(2) NDA or ANDA pathway. In pursuit of this goal, Vici operates a rapid, low-cost, high quality prototyping R&D facility capable of GMP operations in Maryland, USA.
Vici is an end-to-end pharmaceutical R&D company capable of taking projects from inception through FDA approval.
We are experts at formulation development, analytical method development, manufacturing process development and tech transfer, CRO management for BE studies, CMC regulatory documentation, and regulatory filings.